The present invention relates to the use of a compound which inhibits the activity of MKK4 as a medicament for the treatment of a patient suffering from an impaired liver function, to the use of a compound as a medicament for the treatment of liver failure, including acute/fulminant or chronic liver failure and/or for increasing the regeneration of liver tissue in a patient.

The present invention relates to the use of a compound which inhibits the activity of MKK4 as a medicament for the treatment of a patient suffering from an impaired liver function, to the use of a compound as a medicament for the treatment of liver failure, including acute/fulminant or chronic liver failure and/or for increasing the regeneration of liver tissue in a patient.

The present invention relates to the use of a compound which inhibits the activity of MKK4 as a medicament for the treatment of a patient suffering from an impaired liver function, to the use of a compound as a medicament for the treatment of liver failure, including acute/fulminant or chronic liver failure and/or for increasing the regeneration of liver tissue in a patient.

The present invention relates to the use of a compound which inhibits the activity of MKK4 as a medicament for the treatment of a patient suffering from an impaired liver function, to the use of a compound as a medicament for the treatment of liver failure, including acute/fulminant or chronic liver failure and/or for increasing the regeneration of liver tissue in a patient.

The present invention relates to the use of a compound which inhibits the activity of MKK4 as a medicament for the treatment of a patient suffering from an impaired liver function, to the use of a compound as a medicament for the treatment of liver failure, including acute/fulminant or chronic liver failure and/or for increasing the regeneration of liver tissue in a patient.

The present invention relates to certain purines of the following formulae, which act as topoisomerase II catalytic inhibitors: wherein: J is independently: H or NR.sup.N1R.sup.N2; X is independently: O, or S; Q is independently: a covalent bond, C.sub.1-7alkylene, C.sub.2-7alkenylene, C.sub.2-7alkynylene, C.sub.3-7cycloalkylene, C.sub.3-7cycloalkenylene, or C.sub.3-7cycloalkynylene; T is independently: a group A.sup.1 or a group A.sup.2; A.sup.1 is independently: C.sub.6-14carboaryl, C.sub.4-14heteroaryl, C.sub.3-12carbocyclic, or C.sub.3-12heterocyclic; and is independently unsubstituted or substituted; A.sup.2 is independently: H, CN, OH, or O(CO)C.sub.1-7alkyl; R is independently H or a nitrogen ring substituent: R.sup.8 is independently H or a ring substituent; either: each of R.sup.N1 and R.sup.N2 is independently H or a nitrogen substituent; or: R.sup.N1 and R.sup.N2 taken together with the nitrogen atom to which they are attached form a ring having from 3 to 7 ring atoms; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, N-oxides, chemically protected forms, and prodrugs thereof. These compounds are useful in combination with topoisomerase II poisons, such as anthracyclines and epipodophyllotoxins, in the treatment of proliferative conditions (e.g., cancer). These compounds are also useful in the treatment of tissue damage associated with extravasation of a topoisomerase II poison, such as an anthracycline or an epipodophyllotoxin.

##STR00001##

The present invention relates to certain purines of the following formulae, which act as topoisomerase II catalytic inhibitors: wherein: J is independently: H or NR.sup.N1R.sup.N2; X is independently: O, or S; Q is independently: a covalent bond, C.sub.1-7alkylene, C.sub.2-7alkenylene, C.sub.2-7alkynylene, C.sub.3-7cycloalkylene, C.sub.3-7cycloalkenylene, or C.sub.3-7cycloalkynylene; T is independently: a group A.sup.1 or a group A.sup.2; A.sup.1 is independently: C.sub.6-14carboaryl, C.sub.4-14heteroaryl, C.sub.3-12carbocyclic, or C.sub.3-12heterocyclic; and is independently unsubstituted or substituted; A.sup.2 is independently: H, CN, OH, or O(CO)C.sub.1-7alkyl; R is independently H or a nitrogen ring substituent: R.sup.8 is independently H or a ring substituent; either: each of R.sup.N1 and R.sup.N2 is independently H or a nitrogen substituent; or: R.sup.N1 and R.sup.N2 taken together with the nitrogen atom to which they are attached form a ring having from 3 to 7 ring atoms; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, N-oxides, chemically protected forms, and prodrugs thereof. These compounds are useful in combination with topoisomerase II poisons, such as anthracyclines and epipodophyllotoxins, in the treatment of proliferative conditions (e.g., cancer). These compounds are also useful in the treatment of tissue damage associated with extravasation of a topoisomerase II poison, such as an anthracycline or an epipodophyllotoxin.

##STR00001##

Provided are substituted 8-methylquinazolin-4(3H)-one compounds useful as PARP inhibitors for the treatment of cancer and asthma, as well as pharmaceutical compositions comprising them and methods for their synthesis.

Provided are substituted 8-methylquinazolin-4(3H)-one compounds useful as PARP inhibitors for the treatment of cancer and asthma, as well as pharmaceutical compositions comprising them and methods for their synthesis.

Provided herein is a new mercaptopurine form, as a hemihydrate, and methods of making and using the same.